← Back to Clinical Trials
Recruiting NCT06654713

NCT06654713 Commercial or Open Source Closed Loop Impact on Pregnancy Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06654713
Status Recruiting
Phase
Sponsor University of California, San Francisco
Condition Type 1 Diabetes
Study Type OBSERVATIONAL
Enrollment 1,000 participants
Start Date 2025-03-13
Primary Completion 2029-12-31

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Commercial AID systemOpen source AID system

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,000 participants in total. It began in 2025-03-13 with a primary completion date of 2029-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this observational study is to better understand what happens when pregnant people with type 1 diabetes (T1D) use automated insulin delivery (AID) systems. The main questions this study aims to answer are: * What are the maternal and neonatal outcomes with AID system use in pregnancy? * What are the glycemic outcomes with AID system use in pregnancy? * What are the behavioral and emotional outcomes with AID system use in pregnancy? Researchers will compare pregnant people who use commercial AID systems and pregnant people who use open source AID systems to see if outcomes are different with these different types of systems. Participants will be asked to remotely share their AID system data with the research team; complete online surveys regarding behavioral and emotional health; and sign an authorization to release health information to allow the research team to access medical records.

Eligibility Criteria

Inclusion criteria: * Pregnant * Diagnosis of type 1 diabetes (T1D) prior to pregnancy * Active use of automated insulin delivery (AID) system Exclusion criteria: * Diagnosis of other forms of diabetes (gestational diabetes, type 2 diabetes, monogenic diabetes)

Contact & Investigator

Central Contact

Primary Investigator

✉ cosclipstudy@ucsf.edu

📞 (415) 307-9319

Principal Investigator

Nasim Sobhani, MD

PRINCIPAL INVESTIGATOR

University of California, San Francisco

Frequently Asked Questions

Who can join the NCT06654713 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Type 1 Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06654713 currently recruiting?

Yes, NCT06654713 is actively recruiting participants. Contact the research team at cosclipstudy@ucsf.edu for enrollment information.

Where is the NCT06654713 trial being conducted?

This trial is being conducted at San Francisco, United States.

Who is sponsoring the NCT06654713 clinical trial?

NCT06654713 is sponsored by University of California, San Francisco. The principal investigator is Nasim Sobhani, MD at University of California, San Francisco. The trial plans to enroll 1,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology